List of works - Timothy Price

A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

scientific article published on 01 February 2014

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma

scientific article

A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection ⬇️

scientific article published on July 10, 2012

Advanced colorectal cancer treatment options beyond standard systemic therapy

scientific article published on 14 January 2017

Antitumor effect of somatostatin analogs in neuroendocrine tumors.

scientific article published on 14 December 2009

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies

scientific article

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

scientific article published on 06 September 2011

Can we accurately report PTEN status in advanced colorectal cancer?

scientific article

Capecitabine in locally advanced anal cancer, do we need randomised evidence?

scientific article published on 2 March 2017

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

scientific article

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

scientific article

Cetuximab for the treatment of colorectal cancer.

scientific article

Cetuximab in metastatic colorectal cancer.

scientific article published on May 2012

Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research

scientific article

Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor.

scientific article published on 13 November 2013

Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies

scientific article

Contrast induced hyperthyroidism due to iodine excess

scientific article published on 4 November 2009

Curative therapy for rectal cancer

scientific article published on 09 November 2020

Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.

scientific article published on January 2010

Current opinion on optimal treatment for colorectal cancer.

scientific article published on May 2013

Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention

scientific article published on 03 December 2019

Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels.

scientific article

Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?

scientific article published on 16 July 2013

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer

scientific article published on 02 September 2019

Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population.

scientific article published on January 2010

Epidemiology of neuroendocrine cancers in an Australian population.

scientific article published on 24 April 2010

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.

scientific article

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

scientific article published on 12 December 2013

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer

scientific article published on 14 October 2018

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

scientific article

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.

scientific article published on 2 December 2013

Findings in young adults at colonoscopy from a hospital service database audit

scientific article

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy

scientific article published on 07 October 2020

Guillain-Barre syndrome in colorectal cancer

scientific article published on 12 March 2012

Hepatic encephalopathy associated with cancer or anticancer therapy.

scientific article published on January 2013

Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.

scientific article published on September 2007

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

scientific article

Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer

scientific article published on 24 November 2011

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

scientific article

KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model

scientific article

Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.

scientific article published in November 2013

Management of advanced gastric cancer.

scientific article published on April 2012

Management of early stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

scientific article published on 12 April 2020

Management of gastric cancer in Asia: resource-stratified guidelines

scientific article

Moving miRNAs to therapeutic targets in colorectal cancer.

scientific article published on 3 May 2019

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

scientific article

Pancreatic cancer epidemiology and survival in an Australian population.

scientific article published in July 2009

Panitumumab in metastatic colorectal cancer.

scientific article published on 26 June 2013

Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.

scientific article published on January 2014

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

scientific article (publication date: May 2014)

Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.

scientific article

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination ⬇️

scientific article published on November 12, 2011

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

article

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO

scientific article

Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma

scientific article published in February 2004

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer

scientific article published on 24 January 2014

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.

scientific article published on 25 March 2013

Prospective randomized trial of neoadjuvant chemotherapy during the 'wait period' following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial.

scientific article

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

scientific article

Reasons for lower survival from non-Hodgkin's lymphoma among older patients.

scientific article published on July 2004

Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry

scientific article published on 17 October 2020

Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy

scientific article published in February 2013

Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation

scientific article published on 20 February 2019

Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance

scientific article

Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases".

scientific article

Reversing Hyperammonemia in Neuroendocrine Tumors

scientific article

Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial

scientific article published on 03 January 2019

Role of Aquaporin 1 Signalling in Cancer Development and Progression.

scientific article published on 29 January 2017

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.

scientific article

Selective internal radiation therapy for liver metastases from colorectal cancer

scientific article (publication date: 7 October 2009)

Selective internal radiation therapy for liver metastases from colorectal cancer

scientific article

Small Cell Lung Cancer: Patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit

article

South Australian clinical registry for metastatic colorectal cancer.

scientific article

Successfully improving access and accrual to oncology clinical trials

scientific article published on 01 April 2007

Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer: A Retrospective Cohort Study Using a Prospectively Maintained Database to Analyze Survival Outcomes fo

scientific article

Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer.

scientific article published on 3 July 2012

Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.

scientific article published on 14 February 2017

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study

scientific article published on 8 November 2013

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis

scientific article

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.

scientific article

The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17.

scientific article published on 5 February 2014

Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia.

scientific article published on 4 May 2017

Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases

scientific article

“Watchful waiting” for metastatic colorectal cancer, antediluvian or an option to be considered again? ⬇️

scientific article published on March 1, 2012

List of works by Timothy Price

A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma

A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection ⬇️

Advanced colorectal cancer treatment options beyond standard systemic therapy

Antitumor effect of somatostatin analogs in neuroendocrine tumors.

Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

Can we accurately report PTEN status in advanced colorectal cancer?

Capecitabine in locally advanced anal cancer, do we need randomised evidence?

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

Cetuximab for the treatment of colorectal cancer.

Cetuximab in metastatic colorectal cancer.

Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research

Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor.

Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies

Contrast induced hyperthyroidism due to iodine excess

Curative therapy for rectal cancer

Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.

Current opinion on optimal treatment for colorectal cancer.

Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention

Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels.

Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?

Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer

Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population.

Epidemiology of neuroendocrine cancers in an Australian population.

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.

Findings in young adults at colonoscopy from a hospital service database audit

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy

Guillain-Barre syndrome in colorectal cancer

Hepatic encephalopathy associated with cancer or anticancer therapy.

Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model

Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.

Management of advanced gastric cancer.

Management of early stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

Management of gastric cancer in Asia: resource-stratified guidelines

Moving miRNAs to therapeutic targets in colorectal cancer.

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

Pancreatic cancer epidemiology and survival in an Australian population.

Panitumumab in metastatic colorectal cancer.

Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer.

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination ⬇️

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO

Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer

Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.

Prospective randomized trial of neoadjuvant chemotherapy during the 'wait period' following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Reasons for lower survival from non-Hodgkin's lymphoma among older patients.

Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry

Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy

Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation

Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance

Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases".

Reversing Hyperammonemia in Neuroendocrine Tumors

Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial

Role of Aquaporin 1 Signalling in Cancer Development and Progression.

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.

Selective internal radiation therapy for liver metastases from colorectal cancer

Selective internal radiation therapy for liver metastases from colorectal cancer

Small Cell Lung Cancer: Patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit

South Australian clinical registry for metastatic colorectal cancer.

Successfully improving access and accrual to oncology clinical trials

Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer: A Retrospective Cohort Study Using a Prospectively Maintained Database to Analyze Survival Outcomes fo

Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer.

Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence.

The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis